Patents by Inventor Shengdar Tsai

Shengdar Tsai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Increasing specificity for RNA-guided genome editing
    Patent number: 11920152
    Abstract: Methods for increasing specificity of RNA-guided genome editing, e.g., editing using CRISPR/Cas9 systems.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: March 5, 2024
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, James Angstman, Shengdar Tsai
  • METHODS FOR INCREASING EFFICIENCY OF NUCLEASE-INDUCED HOMOLOGY-DIRECTED REPAIR
    Publication number: 20210292795
    Abstract: The present invention relates to methods to improve the absolute rate of homology-directed repair (HDR) and/or to improve the relative rate of HDR compared with non-homologous end joining (NHEJ).
    Type: Application
    Filed: May 26, 2021
    Publication date: September 23, 2021
    Inventors: J. Keith JOUNG, Benjamin KLEINSTIVER, Jason Michael GEHRKE, Shengdar TSAI, James ANGSTMAN, Rebecca Tayler COTTMAN
  • Using RNA-guided FokI nucleases (RFNs) to increase specificity for RNA-guided genome editing
    Patent number: 11098326
    Abstract: Many studies have shown that CRISPR-Cas nucleases can tolerate up to five mismatches and still cleave; it is hard to predict the effects of any given single or combination of mismatches on activity. Taken together, these nucleases can show significant off-target effects but it can be challenging to predict these sites. Described herein are methods for increasing the specificity of genome editing using the CRISPR/Cas system, e.g., using RNA-guided FokI Nucleases (RFNs), e.g., FokI-Cas9 or FokI-dCas9-based fusion proteins.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: August 24, 2021
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Shengdar Tsai
  • Full interrogation of nuclease DSBs and sequencing (FIND-seq)
    Patent number: 11028429
    Abstract: Sensitive, unbiased methods for genome-wide detection of potential off-target nuclease cleavage sites in DNA, e.g., in cell type-specific genomic DNA samples.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: June 8, 2021
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Shengdar Tsai
  • Methods for increasing efficiency of nuclease-induced homology-directed repair
    Patent number: 11021718
    Abstract: The present invention relates to methods to improve the absolute rate of homology-directed repair (HDR) and/or to improve the relative rate of HDR compared with non-homologous end joining (NHEJ).
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: June 1, 2021
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Benjamin Kleinstiver, Jason Michael Gehrke, Shengdar Tsai, James Angstman, Rebecca Tayler Cottman
  • Increasing Specificity for RNA-Guided Genome Editing
    Publication number: 20210130850
    Abstract: Methods for increasing specificity of RNA-guided genome editing, e.g., editing using CRISPR/Cas9 systems.
    Type: Application
    Filed: November 16, 2020
    Publication date: May 6, 2021
    Inventors: J. Keith Joung, James Angstman, Jeffry D. Sander, Morgan Maeder, Shengdar Tsai
  • Increasing specificity for RNA-guided genome editing
    Patent number: 10844403
    Abstract: Methods for increasing specificity of RNA-guided genome editing, e.g., editing using CRISPR/Cas9 systems.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: November 24, 2020
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, James Angstman, Jeffry D. Sander, Morgan Maeder, Shengdar Tsai
  • Comprehensive in vitro reporting of cleavage events by sequencing (CIRCLE-seq)
    Patent number: 10738303
    Abstract: Sensitive, unbiased methods for genome-wide detection of potential CRISPR-Cas9 off-target cleavage sites from cell type-specific genomic DNA samples.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: August 11, 2020
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Shengdar Tsai
  • Using RNA-guided FokI Nucleases (RFNs) to Increase Specificity for RNA-Guided Genome Editing
    Publication number: 20200224222
    Abstract: Many studies have shown that CRISPR-Cas nucleases can tolerate up to five mismatches and still cleave; it is hard to predict the effects of any given single or combination of mismatches on activity. Taken together, these nucleases can show significant off-target effects but it can be challenging to predict these sites. Described herein are methods for increasing the specificity of genome editing using the CRISPR/Cas system, e.g., using RNA-guided FokI Nucleases (RFNs), e.g., FokI-Cas9 or FokI-dCas9-based fusion proteins.
    Type: Application
    Filed: January 24, 2020
    Publication date: July 16, 2020
    Inventors: J. Keith Joung, Shengdar Tsai
  • Genomewide Unbiased Identification of DSBs Evaluated by Sequencing (GUIDE-Seq)
    Publication number: 20200199665
    Abstract: Unbiased, genomewide and highly sensitive methods for detecting mutations, e.g., off-target mutations, induced by engineered nucleases.
    Type: Application
    Filed: December 9, 2019
    Publication date: June 25, 2020
    Inventors: J. Keith Joung, Shengdar Tsai
  • Multiplex Guide RNAS
    Publication number: 20200165587
    Abstract: Methods and constructs for the multiplex expression of highly active CRISPR guide RNAs (gRNAs) from RNA Polymerase II and III promoters, optionally in mammalian cells.
    Type: Application
    Filed: January 6, 2020
    Publication date: May 28, 2020
    Inventors: Shengdar Tsai, J. Keith Joung
  • Using RNA-guided FokI nucleases (RFNs) to increase specificity for RNA-guided genome editing
    Patent number: 10544433
    Abstract: Many studies have shown that CRISPR-Cas nucleases can tolerate up to five mismatches and still cleave; it is hard to predict the effects of any given single or combination of mismatches on activity. Taken together, these nucleases can show significant off-target effects but it can be challenging to predict these sites. Described herein are methods for increasing the specificity of genome editing using the CRISPR/Cas system, e.g., using RNA-guided Foki Nucleases (RFNs), e.g., Fokl-Cas9 or Foki-dCas9-based fusion proteins.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: January 28, 2020
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Shengdar Tsai
  • Multiplex guide RNAs
    Patent number: 10526589
    Abstract: Methods and constructs for the multiplex expression of highly active CRISPR guide RNAs (gRNAs) from RNA Polymerase II and III promoters, optionally in mammalian cells. The present invention is based, at least in part, on the discovery that Csy4, an endoribonuclease that recognizes a short RNA hairpin sequence, can be used to cleave out multiple functional gRNAs encoded on a single longer RNA transcript (produced from an RNA pol II or III promoter) in which the individual gRNAs are separated by Csy4 cleavage sites.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: January 7, 2020
    Assignee: The General Hospital Corporation
    Inventors: Shengdar Tsai, J. Keith Joung
  • Genomewide unbiased identification of DSBs evaluated by sequencing (GUIDE-seq)
    Patent number: 10501794
    Abstract: Unbiased, genomewide and highly sensitive methods for detecting mutations, e.g., off-target mutations, induced by engineered nucleases.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: December 10, 2019
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Shengdar Tsai
  • Using RNA-guided FokI Nucleases (RFNs) to Increase Specificity for RNA-Guided Genome Editing
    Publication number: 20180340189
    Abstract: Many studies have shown that CRISPR-Cas nucleases can tolerate up to five mismatches and still cleave; it is hard to predict the effects of any given single or combination of mismatches on activity. Taken together, these nucleases can show significant off-target effects but it can be challenging to predict these sites. Described herein are methods for increasing the specificity of genome editing using the CRISPR/Cas system, e.g., using RNA-guided Foki Nucleases (RFNs), e.g., FokI-Cas9 or Foki-dCas9-based fusion proteins.
    Type: Application
    Filed: June 8, 2018
    Publication date: November 29, 2018
    Inventors: J. Keith Joung, Shengdar Tsai
  • Using RNA-guided FokI nucleases (RFNs) to increase specificity for RNA-guided genome editing
    Patent number: 10138476
    Abstract: Methods for increasing specificity of RNA-guided genome editing, e.g., editing using CRISPR/Cas9 systems.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: November 27, 2018
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Shengdar Tsai
  • Full Interrogation of Nuclease DSBs and Sequencing (FIND-seq)
    Publication number: 20180265920
    Abstract: Sensitive, unbiased methods for genome-wide detection of potential off-target nuclease cleavage sites in DNA, e.g., in cell type-specific genomic DNA samples.
    Type: Application
    Filed: May 31, 2018
    Publication date: September 20, 2018
    Inventors: J. Keith Joung, Shengdar Tsai
  • Comprehensive In vitro Reporting of Cleavage Events by Sequencing (CIRCLE-seq)
    Publication number: 20180245071
    Abstract: Sensitive, unbiased methods for genome-wide detection of potential CRISPR-Cas9 off-target cleavage sites from cell type-specific genomic DNA samples.
    Type: Application
    Filed: December 22, 2017
    Publication date: August 30, 2018
    Inventors: J. Keith Joung, Shengdar Tsai
  • METHODS FOR INCREASING EFFICIENCY OF NUCLEASE-INDUCED HOMOLOGY-DIRECTED REPAIR
    Publication number: 20180230494
    Abstract: The present invention relates to methods to improve the absolute rate of homology-directed repair (HDR) and/or to improve the relative rate of HDR compared with non-homologous end joining (NHEJ).
    Type: Application
    Filed: October 1, 2015
    Publication date: August 16, 2018
    Inventors: J. Keith JOUNG, Benjamin KLEINSTIVER, Jason Michael GEHRKE, Shengdar TSAI, James ANGSTMAN, Rebecca Tayler COTTMAN
  • Increasing Specificity for RNA-Guided Genome Editing
    Publication number: 20180208921
    Abstract: Methods for increasing specificity of RNA-guided genome editing, e.g., editing using CRISPR/Cas9 systems.
    Type: Application
    Filed: January 12, 2018
    Publication date: July 26, 2018
    Inventors: J. Keith Joung, James Angstman, Jeffry D. Sander, Morgan Maeder, Shengdar Tsai